Patent intelligence · US
US 9539330
Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
Patent details — US 9539330
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 10, 2017
- Expiration
- Jan 5, 2037
- Applicant
- Jazz Pharmaceuticals, Inc.
- Claims
- 26
- CPC classes
- A61K, A61K31/19, A61K31/191, A61K47/02
Quick answer
US 9539330 (Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy) is held by Jazz Pharmaceuticals, Inc.. Status: granted. Granted Jan 10, 2017. Expires Jan 5, 2037 (10 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Jazz Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 26
- CPC classes
- A61K, A61K31/19, A61K31/191, A61K47/02, A61K47/08, A61K47/12
More from Jazz Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12427160
Use of cannabinoids in the treatment of epilepsy
granted -
US 12403136
Cannabinoid derivatives as pharmaceutically active compounds and methods of preparation thereof
granted -
US 12396963
Cannabidiol-type cannabinoid compound
granted -
US 12383512
Cannabidiol-type cannabinoid compound
granted -
US 12383567
Use of cannabinoids in the treatment of epilepsy
granted -
US 12364670
Cannabidiol-type cannabinoid compound
granted -
US 12357586
Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
granted -
US 12350253
Use of cannabinoids in the treatment of dyskinesia associated with parkinson's disease
granted
Related coverage
BBSW AI Solution: Key Insights from the 2026 Event
The BBSW AI Solution event in Foster, USA, promises to unveil critical advancements in AI technology for the pharma industry. Stay tuned for live updates and key takeaways.
BBSW AI Solution 2026: Key Insights and Highlights
The BBSW AI Solution event in 2026 is set to unveil groundbreaking advancements in AI technology. Join us for live coverage and key insights from industry leaders.
Frequently asked questions
What is US patent 9539330?
US 9539330 (Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy) is held by Jazz Pharmaceuticals, Inc.. Status: granted. Granted Jan 10, 2017. Expires Jan 5, 2037 (10 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9539330?
Jazz Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 89 pharmaceutical patents for this assignee.
When does US 9539330 expire?
Our index shows an expiration date of Jan 5, 2037 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.